ASH 2020 Conference Review

In this review:

Worsening acquired TTP despite daily therapeutic plasma exchange
First-line treatment pathways for newly diagnosed ITP
Haematological responses to pegcetacoplan vs. eculizumab in PNH
Suboptimal iron deficiency screening in pregnancy in a high-resource setting
Biomarkers in steroid-refractory GVHD treated with ruxolitinib vs. best available therapy
Asciminib vs. bosutinib in chronicphase CML previously treated with ≥2 TKIs
Novel targeted therapies for relapsed/refractory CLL after Murano trial
BAX-mutated clonal haematopoiesis after long-term venetoclax for relapsed/refractory CLL
RIC allogeneic SCT vs. hypomethylators/supportive care in advanced MDS
CV disease is leading cause of death in first TTP survivors

Please login below to download this issue (PDF)